Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003 – News Press

It may be sent to sexual partners, even if your disease is asymptomatic. Daian Cheng, Ph.D., GlobalData’s Analyst covering Infectious Diseases, says that although both vaccines have novel mechanisms of action that can partially address some of the unmet needs in current GH management, GEN-003 possesses stronger commercial and clinical attributes according to available data. The study will seek to evaluate the safety and tolerability of GEN-003 and its ability to stimulate the immune system, as well as determine the impact of the vaccine upon viral shedding, which is considered to be a marker of disease recurrence and transmission. 8, 2016 for the 4th Annual Pediatric Surgical Innovation Symposium, a one-day conference and Medtech Innovation Showcase focused on stimulating pediatric device innovation. Using ATLAS™, Genocea’s proprietary high-throughput screening platform, they identified HSV-2 proteins (or antigens) associated with protective immune responses in volunteers who had no evidence of infection but had been exposed to HSV-2, or who had relatively mild HSV-2 infections. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that the peer-reviewed journal Virology has published a paper describing how Genocea used it’s ATLAS™ platform to identify the herpes simplex virus 2 (HSV-2) antigens for its GEN-003 clinical program.

Wald and her team presented the initial findings of the first-in-human clinical trial of the novel GEN-003 T cell vaccine Sept. — Genocea Biosciences, a vaccine discovery and development company, announced Feb. I think it shows how optimistic they are about this drug and it wil be the next drug approved for the treatment of hsv. The addition of these patents complements the novel antigens discovered by Genocea’s unique and proprietary antigen discovery technology. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company’s immunotherapy candidate against herpes simplex-type 2 (HSV-2). News content has been transferred by the staff of this site, assuming diligence and good faith of the original publisher of the article.

GEN-003 demonstrated statistically significant reductions compared to baseline in the rate of viral shedding 12 months after dosing as well as sustained efficacy across secondary clinical endpoints, in each case across multiple dose groups. (GNCA) soared 95% today following the release of positive data from its mid-stage genital herpes clinical trial. , a biopharmaceutical company developing T cell-directed vaccines and immunotherapies against serious infectious diseases, announced today the presentation of final data from the Phase 1/2a study of GEN-003, the company’s immunotherapy candidate for treatment of genital herpes. NVAX is licensing Matirix M out for uses that will not compete with its vaccines but will reserve it for itself to give a large advantage in markets addressed by its vaccines. In addition, the study was designed to demonstrate proof-of-concept that GEN-003 can reduce HSV-2 viral shedding, a measure of viral activity, and the genital lesion rate, the percentage of days during which the subjects experienced visible herpes outbreaks or lesions. Research and follow-up could take several weeks.

Genocea’s lead product candidate is GEN-003, a therapeutic vaccine for genital herpes. Hetherington points out that the assessment of genital lesions is subjective and that the placebo group was small (1/7 of 310) and results may have been influenced by random chance. In a Phase 1/2a study, patients showed statistically significant reductions in viral shedding and genital lesion rates of up to 52 percent and 65 percent respectively, with a durability of effect to six months after dosing in the 30µg dose group. A replay of the webcast will be archived for 30 days following the presentation. Genocea will also use funds to advance its deep research pipeline, including prophylactic vaccine programs addressing Chlamydia trachomatis, Streptococcus pneumoniae, HSV-2 and Plasmodium falciparum (malaria). The results, which are available today in the print edition of Journal of Virology, show that vaccination with GEN-003, along with Matrix-M™ adjuvant, induced antigen- and virus-specific immune responses and improved outcomes in preclinical models of the disease.

Nearly everyone is anxiously waiting to see what Apple is going to introduce. — Genocea Biosciences, Inc., a clinical-stage company developing novel T cell vaccines, announced today that it has filed a registration statement on Form S-1 with the U.S.

You may also like